Ciclesonide Market Landscape By Manufacturing Base, Trends, Influence factors, Revenue, Wholesalers, Opportunities and Forecasts 2021-2027

Global Ciclesonide Market

The Global Ciclesonide Market, by Indication (Allergic Rhinitis and Asthma), by Dosage Form (Nasal Spray and Aerosol), and by Region (North America, Asia Pacific, Latin America, Europe, Middle East, and Africa) had a market valuation of US$ 565.4 million in 2018, and is forecast to grow at a CAGR of 1.9 percent during the forecast period (2018 – 2026).

Inhaled corticosteroids (ICS) like ciclesonide are the foundation of asthma and chronic obstructive pulmonary disease or COPD therapy. A mixture of ICS and short- or long-acting bronchodilators is used to cure the most of asthma patients. The efficacy of inhaled corticosteroids in the treatment of asthma and COPD is encouraging the use of ciclesonide in the future. As per research published in the BMJ Journal in November 2018, triple therapy, which included a LAMA or long-acting muscarinic antagonist, a LABA (long-acting agonist), and an ICS (inhaled corticosteroid), decreased rate of acute or chronic COPD exacerbations, improved cardiac function, and a higher health-related quality of life in patients than dual therapy.

Get Sample Here

Browse 26 Market Data Tables and 24 Figures spread through 126 Pages and in-depth TOC on ‘Ciclesonide Market, by Indication (Allergic Rhinitis and Asthma), by Dosage Form (Nasal Spray and Aerosol), and by Region (North America, Asia Pacific, Latin America, Europe, Middle East, and Africa) – Global Forecast to 2026’

During the forecast period, the release and approval of new ciclesonide products in key areas is projected to offer a favorable environment for the global ciclesonide market to develop. Sunovion Pharmaceuticals Inc. gained FDA clearance and marketed Zetonna nasal spray for the cure of different rhinitis in the U.S. in 2012. Omnaris nasal spray was released in the United Arab Emirates in 2012 by Nycomed, a division of Takeda Pharmaceutical Company Ltd., for the cure of different rhinitis in adults and adolescents over the age of 12.

Major market competitors are pursuing strategic mergers and acquisitions in order to get access to the lucrative ciclesonide market and expand their portfolio of ciclesonide products. During the forecast period, strategic mergers and acquisitions are projected to assist the growth of the global ciclesonide market. AstraZeneca Plc., purchased Takeda Pharmaceutical Company Ltd.’s lung division in 2015, expanding its portfolio with Alvesco, Omnaris ciclesonide. Sunovion Pharmaceuticals Inc. sold its ciclesonide products ALVESCO Inhalation Aerosol, OMNARIS Nasal Spray, and ZETONNA Nasal Aerosol to Covis Pharma B.V. in the U.S. in 2017.

Key Takeaways

Due to increased participation of major competitors to get larger market share by organic and in-organic tactics such as new product introduction, merger, and divestment, the global ciclesonide market is estimated to grow at a CAGR of 9% over the forecast period.

In 2017, the allergic rhinitis sector accounted for the largest market share among indications. As per data given by Allergy U.K., allergic rhinitis is a relatively prevalent non-infectious rhinitis that affects between 10% and 30% of all adults and up to 40% of children in the U.K. in 2013. According to the same source, 57 percent of adult patients with allergy rhinitis and up to 88 percent of children with allergy rhinitis experience sleep issues, including micro-arousals. Due to the increasing frequency of allergic rhinitis, demand for ciclesonide, which is commonly used to diagnose allergy rhinitis, is projected to grow.

Due to easy and direct inhalation of ciclesonide by aerosol, which allows for the delivery of an adequate amount of medication to the patient, the aerosol segment contributed for the largest revenue in the market in 2017. Moreover, aerosol treatments are commonly used to treat respiratory problems such as asthma in adults and adolescents aged 12 and up, as well as related symptoms with SAR (seasonal allergic rhinitis) and PAR (perennial allergic rhinitis) in adults and children aged 12 and over.

Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/2291

Ciclesonide Market – Competitive Landscape

Key players functioning in the global prosthetic liners market consists of AstraZeneca Plc, Cipla Limited, Sun Pharmaceutical Industries Ltd. and Apotex Inc.

Main points in Ciclesonide Market Report Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Ciclesonide Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Ciclesonide Industry Impact

Chapter 2 Global Ciclesonide Competition by Types, Applications, and Top Regions and Countries
2.1 Global Ciclesonide (Volume and Value) by Type
2.3 Global Ciclesonide (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Ciclesonide Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Ciclesonide Market Analysis
Chapter 6 East Asia Ciclesonide Market Analysis
Chapter 7 Europe Ciclesonide Market Analysis
Chapter 8 South Asia Ciclesonide Market Analysis
Chapter 9 Southeast Asia Ciclesonide Market Analysis
Chapter 10 Middle East Ciclesonide Market Analysis
Chapter 11 Africa Ciclesonide Market Analysis
Chapter 12 Oceania Ciclesonide Market Analysis
Chapter 13 South America Ciclesonide Market Analysis
Chapter 14 Company Profiles and Key Figures in Ciclesonide Business
Chapter 15 Global Ciclesonide Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com